OpenSourceMalaria:Triazolopyrazine (TP) Series: Difference between revisions
Matthew Todd (talk | contribs) (→PfATP4 Activity: added scheme of structures of original 5 PfATP4 activities) |
Matthew Todd (talk | contribs) |
||
Line 22: | Line 22: | ||
The following five compounds were evaluated. Structures, potency and metabolism/solubility are here. | The following five compounds were evaluated. Structures, potency and metabolism/solubility are here. | ||
[[Image:Original PfATP4 Activities.tif|thumb|center| | [[Image:Original PfATP4 Activities.tif|thumb|center|600px|The Five Compounds Initially Evaluated for PfATP4 activity]] | ||
MMV669000: (potency: inactive) | MMV669000: (potency: inactive) |
Revision as of 21:19, 27 August 2013
Open Source Malaria Series 4: The Triazolopyrazine (TP) Series
Introduction
Preamble
This series of compounds arises from industrial work that cannot be disclosed, followed by some hit-to-lead work funded directly by MMV which can. The series is based on a triazolopyrazine core. There is evidence that these compounds may be PfATP4 inhibitors. OSM started to look at this series following a decision by MMV to release their data into the public domain.
Current Aims
Further hit-to-lead work. Validate PfATP4 activity. Improve potency and drug likeness.
Prior Knowledge of the Series
Potency of Hits and Analogs
PfATP4 Activity
The following five compounds were evaluated. Structures, potency and metabolism/solubility are here.
MMV669000: (potency: inactive)
MMV669304: (potency: 280 nM)
MMV669360: (potency: 356 nM)
MMV669542: (potency: 185 nM)
MMV669848: (potency: 114 nM)
(Note the correlation: compound inactive in PfATP4 assay is the inactive analog)
Strings
MMV669000: O=C(N1CC(C=CC=C2)=C2C1)C3=CN=CC4=NN=C(C5=CC=C(OC(F)F)C=C5)N43; InChI=1S/C21H15F2N5O2/c22-21(23)30-16-7-5-13(6-8-16)19-26-25-18-10-24-9-17(28(18)19)20(29)27-11-14-3-1-2-4-15(14)12-27/h1-10,21H,11-12H2
MMV669304: FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CCCC4=CC=CC=C4)N32; InChI=1S/C21H18F2N4O/c22-21(23)28-18-11-9-16(10-12-18)20-26-25-19-14-24-13-17(27(19)20)8-4-7-15-5-2-1-3-6-15/h1-3,5-6,9-14,21H,4,7-8H2
MMV669360: FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(COCC4=CC=C(F)C(F)=C4)N32; InChI=1S/C20H14F4N4O2/c21-16-6-1-12(7-17(16)22)10-29-11-14-8-25-9-18-26-27-19(28(14)18)13-2-4-15(5-3-13)30-20(23)24/h1-9,20H,10-11H2
MMV669542: FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(C(NC4=CC=CC(Cl)=C4)=O)N32; InChI=1S/C19H12ClF2N5O2/c20-12-2-1-3-13(8-12)24-18(28)15-9-23-10-16-25-26-17(27(15)16)11-4-6-14(7-5-11)29-19(21)22/h1-10,19H,(H,24,28)
MMV669848: FC(F)OC(C=C1)=CC=C1C2=NN=C3C=NC=C(CN4CC(C=CC=C5)=C5C4)N32; InChI=1S/C21H17F2N5O/c22-21(23)29-18-7-5-14(6-8-18)20-26-25-19-10-24-9-17(28(19)20)13-27-11-15-3-1-2-4-16(15)12-27/h1-10,21H,11-13H2